Continuing Education
for Urology & GU Oncology Clinicians

Conference Coverage: ESMO 2019 Kidney

Barcelona, Spain (UroToday.com) NIVOREN GETUG AFU 26 is a French multicenter, prospective, phase 2 study that reported safety and efficacy of nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) in a “real world setting.” Results, presented at the GU ASCO 2019 meeting, were notable for a response rate of 21% with a median progression-free survival of 3.7 months and overall survival of 24.5 months after a median follow-up of 23.8 months. In this abstract, the investigators report results of a translational study evaluating whether CD8 infiltration and PD-L1 expression are associated with outcomes in patients with mccRCC treated with nivolumab.

Non-Accredited

Barcelona, Spain (UroToday.com)  Immune-checkpoint inhibitor therapy has yielded notable clinical benefits for patients with metastatic renal cell carcinoma (mRCC).1,2 ADATPeR is the first prospective study evaluating the role of anti-PD1 agents in the neoadjuvant setting prior to cytoreductive nephrectomy in treatment-naïve patients with metastatic clear cell renal cell carcinoma. At the ESMO 2019 clinical congress, Dr. Au presented results of their multiomic analyses to resolve spatial heterogeneity and temporal dynamics in putative biomarkers of response to anti-PD1 blockade.

Non-Accredited

Barcelona, Spain (UroToday.com)  The International Kidney Cancer Coalition (IKCC) is a federation of 45 affiliated patient organizations representing 1.2 million patients worldwide that is committed to reducing the global burden of kidney cancer. To date, a large-scale global survey of RCC patients to capture real world experiences among clinicians and patients has never been undertaken. At the ESMO 2019 clinical congress, Rachel Giles and colleagues presented results of a global patient survey in 43 countries.

Non-Accredited

Barcelona, Spain (UroToday.com) The role of upfront cytoreductive nephrectomy (uCN) in patients with metastatic renal cell carcinoma (mRCC) is currently under debate as systemic therapy alone (sunitinib) was recently demonstrated to be noninferior.1 Since that time, combination immunotherapy and immunotherapy plus VEGF tyrosine kinase inhibitor (TKI) combination regimens have demonstrated efficacy in patients with previously-untreated mRCC. JAVELIN Renal 101 demonstrated a significant improvement in progression-free survival (PFS) with avelumab plus axitinib (A + Ax) versus sunitinib (median PFS 13.8 vs 8.4 months, HR 0.69, p < 0.001) in patients with previously untreated clear cell mRCC.2 Clinical benefit was seen in patients irrespective of prior uCN. The efficacy of this therapy on the primary tumor is unknown. In this abstract, the investigators report findings from a post hoc analysis of patients enrolled in JAVELIN Renal 101 with renal target lesions who had not undergone uCN. 

Non-Accredited

Barcelona, Spain (UroToday.com) ADAPTeR (NCT02446860) is the first prospective study evaluating the role of anti-PD1 agents in the neoadjuvant setting prior to cytoreductive nephrectomy in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). The primary endpoint of this study was safety with secondary endpoints of objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). An additional exploratory endpoint was multi-omic analyses to resolve spatial heterogeneity and temporal dynamics in putative biomarkers of response to anti-PD1 blockade.

Non-Accredited